Adial pharmaceuticals reports third quarter 2023 financial results and provides business update

Advancing discussions with potential strategic partners received frost & sullivan's 2023 north american precision medicine for addiction disorders technology innovation leadership award closed $4 million private placement priced at-the-market under nasdaq rules; extends cash runway into q4 2024 charlottesville, va., nov. 14, 2023 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the third quarter of 2023.
ADIL Ratings Summary
ADIL Quant Ranking